Multiple sclerosis journal - experimental, translational and clinical · 2026
Real-world adherence to and persistence with ofatumumab, infusion, oral, and other self-injectable disease-modifying therapies in patients with multiple sclerosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tai Ming-Hui, Brown Brandon, Taiji Riley, Faucher Ariane, Vekeman Francis, Ionescu-Ittu Raluca, Gadkari Abhijit
Аннотация
BACKGROUND: Treatment schedule complexity and route of administration may influence patient adherence and persistence. Limited real-world evidence exists comparing these outcomes across treatments for multiple sclerosis (MS).
OBJECTIVE: To examine 18- and 24-month adherence/persistence of ofatumumab (OMB) and other approved disease-modifying therapies (DMTs).
METHODS: Optum Clinformatics® Data Mart data were used to identify adult patients with MS who initiated treatment with an approved DMT from August 20, 2019, to December 31, 2023. Patients were stratified into four treatment groups: OMB, infusion DMTs, oral DMTs, and other injectable DMTs.
RESULTS: After propensity score matching, adherence to OMB was significantly higher than to oral DMTs (18 months: 73% vs. 51% [p < .001]; 24 months: 69% vs. 47% [p < .001]) and was also higher with OMB than with other injectable agents (18 months: 74% vs. 40% [p < .001]; 24 months: 70% vs. 35% [p < .001]). Adherence to OMB and infusion DMTs was comparable (18 months: 74% vs. 70% [p = .31]; 24 months: 70% vs. 65% [p = .24]). Similar patterns were observed for persistence between the groups.
CONCLUSION: These findings suggest OMB is a convenient, effective, self-administered alternative to infusion therapies.
OBJECTIVE: To examine 18- and 24-month adherence/persistence of ofatumumab (OMB) and other approved disease-modifying therapies (DMTs).
METHODS: Optum Clinformatics® Data Mart data were used to identify adult patients with MS who initiated treatment with an approved DMT from August 20, 2019, to December 31, 2023. Patients were stratified into four treatment groups: OMB, infusion DMTs, oral DMTs, and other injectable DMTs.
RESULTS: After propensity score matching, adherence to OMB was significantly higher than to oral DMTs (18 months: 73% vs. 51% [p < .001]; 24 months: 69% vs. 47% [p < .001]) and was also higher with OMB than with other injectable agents (18 months: 74% vs. 40% [p < .001]; 24 months: 70% vs. 35% [p < .001]). Adherence to OMB and infusion DMTs was comparable (18 months: 74% vs. 70% [p = .31]; 24 months: 70% vs. 65% [p = .24]). Similar patterns were observed for persistence between the groups.
CONCLUSION: These findings suggest OMB is a convenient, effective, self-administered alternative to infusion therapies.